Monte Rosa Therapeutics Inc (GLUE) is a Healthcare · Biotechnology company listed on NASDAQ. Price $12.13 (-3.73%), Market cap $1.61B, 52-week low–high $3.70 ~ $25.31.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric
Financial statements, price targets, institutional (13F) holdings and related news for Monte Rosa Therapeutics Inc are updated in real time on BlackAll Trade.
Monte Rosa Therapeutics Inc trades at $12.13 (-3.73%). Real-time quotes and charts are available on BlackAll Trade.
Monte Rosa Therapeutics Inc has a market cap of about $1.61B.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively d